Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity

Biomedicines

DanielA. Vallera¹  RobertJ. Kreitman² 

[1] Laboratory of Molecular Cancer Therapeutics, Masonic Cancer Center, Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA;National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA;

关键词: diphtheria toxin;    pseudomonas exotoxin;    immunogenicity;    B-cell malignancies;    CD19;    CD22;    deimmunized;    immunotoxin;    chemo-immunosuppression;   

DOI  :  10.3390/biomedicines7010001

来源: DOAJ

【 摘 要 】

Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-toxin response of the treated patient. Since some of our most effective toxins are bacterial in nature and bacterial proteins are highly immunogenic, this review describes some efforts to address this pressing issue.

【 授权许可】

Unknown